Get the Stockscreener App
3.33
3.48%
-0.12
After Hours:
3.36
0.03
+0.90%
Sight Sciences Inc stock is traded at $3.33, with a volume of 180.74K.
It is down -3.48% in the last 24 hours and down -19.37% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$3.45
Open:
$3.42
24h Volume:
180.74K
Relative Volume:
1.13
Market Cap:
$172.15M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-2.9211
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
-6.46%
1M Performance:
-19.37%
6M Performance:
+18.93%
1Y Performance:
-57.20%
1-Day Range:
$3.29
$3.49
1-Week Range:
$3.29
$3.63
52-Week Range:
$2.03
$7.78
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.33 | 178.37M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Analyzing Sight Sciences Inc. with risk reward ratio chartsFree Trade Ready Stock Watch for Short Term - Newser
Will Sight Sciences Inc. see short term momentumMarket Liquidity and Price Flow Analysis - Newser
How volatile is Sight Sciences Inc. stock compared to the marketFinancial News Planner For Consistent Profits - jammulinksnews.com
Should I buy Sight Sciences Inc. stock before earningsAI Trade Signal Forecast with Chart Logic - Newser
Why Sight Sciences Inc. stock attracts strong analyst attentionFree AI Forecast for Trending Stocks - Newser
How Sight Sciences Inc. stock performs during market volatility3-Day Market Movement Forecast Analysis - Newser
Is Sight Sciences Inc. Stock a Good Fit for Conservative InvestorsOversold Stock Bounce Playbook Generator - Newser
What makes Sight Sciences Inc. stock price move sharplyRisk Aware Swing Trade Analysis Insights - Newser
Sight Sciences Announces the Results of a Cost-Utility - GlobeNewswire
New Clinical Study: TearCare Outperforms Standard Therapy in Both Cost and Effectiveness for Dry Eye Disease - Stock Titan
Will Sight Sciences Inc. outperform the marketFree Stock Portfolio Allocation Guidance - Newser
Multi Factor Analysis Ranks Sight Sciences Inc. as Strong BuySwing Setup With Technical Confirmation Explained - metal.it
Risk adjusted return profile for Sight Sciences Inc. analyzedPortfolio Risk Distribution Analysis Tool - Newser
Sight Sciences Announces the Publication of the 24-Month - GlobeNewswire
Will Sight Sciences Inc. price bounce be sustainableFree Daily Volume Spike Trading Signals - Newser
Clinical Trial: TearCare Outperforms Restasis, Provides 2-Year Dry Eye Relief with Just Two Treatments - Stock Titan
Is it the right time to buy Sight Sciences Inc. stockStock Market Updates For Beginners - jammulinksnews.com
What are analysts’ price targets for Sight Sciences Inc. in the next 12 monthsPost Market Watchlist For Every Investor - jammulinksnews.com
How does Sight Sciences Inc. generate profit in a changing economyUnprecedented profits - jammulinksnews.com
What is the dividend policy of Sight Sciences Inc. stockTrack top-performing stocks effortlessly - jammulinksnews.com
What are the technical indicators suggesting about Sight Sciences Inc.Unlock your portfolio’s hidden potential - jammulinksnews.com
When is Sight Sciences Inc. stock expected to show significant growthTriple-digit wealth increases - jammulinksnews.com
Should I hold or sell Sight Sciences Inc. stock in 2025High-velocity gains - jammulinksnews.com
Intrinsic Value of Sight Sciences Inc. Stock: Is It Undervalued or OvervaluedFree Discussion Group - Newser
Published on: 2025-07-27 17:05:15 - jammulinksnews.com
Is Sight Sciences Inc. a good long term investmentFree Investment Case Studies - PrintWeekIndia
Sight Sciences Inc. Stock Analysis and ForecastExceptional trading performance - PrintWeekIndia
Insider Spends US$452k Buying More Shares In Sight Sciences - 富途牛牛
What analysts say about Sight Sciences Inc. stockHigh-return market picks - PrintWeekIndia
Sight Sciences, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025 - Nasdaq
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewswire
Sight Sciences, Eyecare Tech Leader, Sets Q2 2025 Earnings Release and Conference Call Details - Stock Titan
What drives Sight Sciences Inc. stock priceAccelerated capital growth - Autocar Professional
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):